CN Patent

CN112996561A — 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用

Assigned to Alexion Pharmaceuticals Inc · Expires 2021-06-18 · 5y expired

What this patent protects

提供了阵发性睡眠性血红蛋白尿症(PNH)的临床治疗方法，所述方法包括向患者施用抗C5抗体或其抗原结合片段，其中所述抗C5抗体或其抗原结合片段是根据特定临床剂量方案(即，以特定剂量并根据特定给药时间表)皮下施用(或供皮下施用)。在一个实施方案中，所述患者先前已经用依库珠单抗治疗。

USPTO Abstract

提供了阵发性睡眠性血红蛋白尿症(PNH)的临床治疗方法，所述方法包括向患者施用抗C5抗体或其抗原结合片段，其中所述抗C5抗体或其抗原结合片段是根据特定临床剂量方案(即，以特定剂量并根据特定给药时间表)皮下施用(或供皮下施用)。在一个实施方案中，所述患者先前已经用依库珠单抗治疗。

Drugs covered by this patent

zilucoplan-sodium (ZILUCOPLAN SODIUM)

Patent Metadata

Patent number: CN112996561A
Jurisdiction: CN
Classification: —
Expires: 2021-06-18
Drug substance claim: No
Drug product claim: No
Assignee: Alexion Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.